Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MESA
- Development stage
- Phase 2
- Lead developer
- Xijing Hospital
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Intravenous
01
Overview
**MESA** is a multi-agent antineoplastic chemotherapy regimen comprising methotrexate, etoposide, dexamethasone, and pegaspargase, a pegylated L-asparaginase. It has been studied with radiotherapy for early-stage extranodal natural killer/T-cell lymphoma, nasal type. Methotrexate inhibits dihydrofolate reductase and folate-dependent nucleotide synthesis; etoposide poisons DNA topoisomerase II; dexamethasone activates the glucocorticoid receptor; and pegaspargase depletes circulating L-asparagine, exploiting lymphoma-cell dependence on extracellular asparagine. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=4387))
- Other names
- MESA chemotherapy regimenmethotrexate + etoposide + dexamethasone + pegaspargase
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)DHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on MESA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MESA.